Bifikafusp alfa

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameBifikafusp alfa
Drug Alias NameL19-IL2 fusion proteinDarleukinL19-IL-2
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-2 stimulantsFibronectin modulators
TargetsInterleukin-2Fibronectin
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPhilogen Spa
China Registration ClassN/A

Develop Information

Active CompaniesPhilogen Spa
Inactive CompaniesMaastricht University Medical Center
Active IndicationsPancreatic NeoplasmsColorectal NeoplasmsCarcinoma, Basal Cell +[7] 
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A